The Antibody Therapy Market is likely to thrive at a good CAGR of 13.4% between 2023 and 2033. The market is anticipated to cross a market share of US$ 824.0 billion by 2033, while it is expected to be valued at US$ 235.0 billion in 2023.

• Higher penetration of adverse diseases like cancer, and COVID-19 spread, has fueled the demand for immunotherapy and antibody therapies.
• Cell-therapy's effectiveness on tumor cells in cancer is expanding the antibody therapy market size. Furthermore, the existing healthcare systems adding advanced therapy options in their treatment procedures are likely to help cancer patients in the future.
• Patients with cancer and other cell and immunity-related diseases are opting for antibody therapy over chemotherapy for lower side effects and higher effectiveness.
• Monoclonal antibody therapy, which also works as passive immunotherapy, helps the immune system in retaining the new cells and strengthening the overall protective layer that saves from diseases.
• New cancer and cell therapy procedures, along with the emerging new therapeutic antibody derivatives, are gaining traction in the market, along with the expanding research and development

Request Sample Report: https://www.futuremarketinsights.com/reports/sample/rep-gb-14362

Key Points

1. The United States market leads the space in terms of market share and CAGR. The market is expected to cross a value of US$ 291.9 billion by 2033. The regional market is expected to thrive at a CAGR of 13.1% between 2023 and 2033.
2. The Chinese antibody therapy market is another significant Asian market. It thrives at a steady CAGR of 12.7% during the forecast period. The market is likely to reach a value of US$ 59.1 billion by 2033. Asian economies like India and China are building their healthcare infrastructure by advancing them with the latest therapeutic solutions to high-risk diseases like cancer.
3. Monoclonal antibodies are likely to thrive in the antibody type category, as it provides immediate and short-term immunity from conditions like COVID-19. It is expected to thrive at a CAGR of 13.2% during the forecast period.
4. The hospital segment leads the end-user category with a CAGR of 12.6% between 2023 and 2033. The growth is attributed to the bigger budget, higher patient traffic, and easy availability of therapeutic experts.

Competitive Landscape

The key competitors create better packages with advanced cell-therapy solutions that deliver treatment with lesser side effects and higher effectiveness. Key competitors also merge, acquire, and partner with other companies to increase the supply chain and distribution channel. The key players in the market are: F. Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Bristol-Myers Squibb Company, Johnson Johnson Services, Inc.

For instance:

• Amgen Inc. has introduced its monoclonal antibody that holds bioengineered molecules, specially designed to target protein involved in different types of diseases.
• AbbVie Inc. has launched the first fully human monoclonal antibody, along with the antibody drug conjugates, that applies the target of an antibody that delivers a therapeutic agent. The company’s other research targets include interleukin-1, interleukin-23, and JAK (Janus Kinase Inhibitors)

Key Segments

By Type:

• Monoclonal Antibodies
  • Oncology, Autoimmune Disease
  • Infectious Disease
  • Other
• Antibody Drug Conjugates

By End User:

• Hospitals
• Specialty Centers
• Others

By Region

• North America
• Latin America
• Europe
• Asia Pacific (APAC)
• Middle East Africa (MEA)